Denise Hernandez
Nurse Practitioner · Goodyear, AZNPI 1912398900
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 28.9% of the total. Reporting peaked in 2022 at $786 and has fallen 64.1% since, to $282 in 2025. Among nurse practitioner clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $14.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$725
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$678
- Almatica Pharma LLC$301
- Bausch Health US, LLC$169
- Otsuka America Pharmaceutical, Inc.$109
- Takeda Pharmaceuticals U.S.A., Inc.$85
- plus $441 from 14 others
What the payments were for
- Food & beverage$2,46198%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $725 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $678 |
| Almatica Pharma LLC | 19 | $301 |
| Bausch Health US, LLC | 9 | $169 |
| Otsuka America Pharmaceutical, Inc. | 6 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $85 |
| Supernus Pharmaceuticals, Inc. | 5 | $79 |
| Neurocrine Biosciences, Inc. | 3 | $67 |
| Sunovion Pharmaceuticals Inc. | 5 | $51 |
| Pfizer | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Novo Nordisk | 1 | $32 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Alfasigma USA, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Alkermes, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
How this compares
$2,508 in reported general payments places this provider in the 90th percentile of 1,719 nurse practitioner providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 11 | $170 |
| Zolpidem Tartrate ErZolpidem Tartrate | 11 | $46 |
| Temazepam | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Goodyear
- Ann MooreGlendale$208K
- Sandra KurtinTucson$201K
- Kristen HerzogScottsdale$162K
- Krista ArredondoChandler$133K
- Shannon MorgensternOro Valley$71K
- Helena In't VeldPhoenix$64K
- Steven KalfusChandler$43K
- Dustin NickersonPhoenix$39K
- Shannon BoffeliFlagstaff$31K
- Kelley RoneScottsdale$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.